Kidney transplantation is the target method of treating chronic kidney disorders. It improves the comfort of patient life by eliminating the need for repeated dialysis. The aim of the study was to examine the correlation between tacrolimus (TAC) dose and genetic variation for interleukin-10 (IL-10) and its effect on the therapeutic outcome. In addition, the correlations between the IL-10 polymorphism and the clinical and the biochemical parameters of TAC patients were also analyzed. The study included 209 subjects after kidney transplantation, who received TAC every 12 and 24 h. Drug concentrations in blood, selected morphological and biochemical parameters, and the genetic variation of IL-10 (-1082A > G) which may affect immunosuppressant dosage and risk of acute graft rejection were analyzed. Genetic analyses were performed using real-time PCR. No significant correlations between the clinical and the biochemical parameters and IL-10 -1082A > G polymorphism for patients receiving TAC after kidney transplantation were found. The analysis of the correlation between TAC dose and IL-10 genetic variation for the −1082A > G polymorphism revealed that patients with the AA genotype required lower immunosuppressive drug doses (AA: 3.54 ± 2.38 mg/day vs AG: 6.18 ± 5.10 mg/day, GG: 4.44 ± 3.01 mg/day). Furthermore, frequencies of the genotypes for the IL-10 −1082A > G polymorphism were characterized by a significantly higher frequency of the AA genotype among TAC 24 as compared to TAC 12 patients. The results of the study indicated that the IL-10 −1082A > G polymorphism may in fact influence the TAC dose. The biochemical parameters of the renal profile in relation to the IL-10 genetic variations were not indicative of higher risk of acute rejection after transplantation.

肾脏移植是治疗慢性肾脏疾病的目标方法。它消除了重复透析的需要，提高了患者生活的舒适度。该研究的目的是检查他克莫司（TAC）剂量与白介素10（IL-10）遗传变异之间的相关性及其对治疗效果的影响。此外，还分析了IL-10多态性与TAC患者的临床和生化参数之间的相关性。该研究包括209名肾脏移植后的受试者，每12和24小时接受一次TAC。分析了血液中的药物浓度，选定的形态和生化参数以及可能影响免疫抑制剂剂量和急性移植排斥反应风险的IL-10的遗传变异（-1082A> G）。使用实时PCR进行遗传分析。肾移植后接受TAC的患者的临床和生化参数与IL-10 -1082A> G多态性之间无显着相关性。对于-1082A> G多态性，TAC剂量与IL-10遗传变异之间的相关性分析表明，具有AA基因型的患者需要较低的免疫抑制药物剂量（AA：3.54±2.38 mg / day相对于AG：6.18±5.10mg /天，GG：4.44±3.01mg /天。此外，IL-10 -1082A> G多态性的基因型频率以TAC 24患者中的AA基因型频率显着高于TAC 12患者为特征。研究结果表明，IL-10 -1082A> G多态性实际上可能影响TAC剂量。与IL-10基因变异有关的肾脏特征的生化参数并不表示移植后发生急性排斥反应的风险较高。